Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 8.79 is 31% above its 3-year average of 6.71, around the middle of its 3-year range (0.00–16.81).
As of the fiscal period ended Tuesday, June 30, 2026. 17.37% below its 12-month average of 10.63.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 8.79.
QUICK RATIO (ACID-TEST)
8.79
QUICK RATIO (ACID-TEST) AVG TTM
10.63
QUICK RATIO (ACID-TEST) AVG 3Y
7.23
QUICK RATIO (ACID-TEST) AVG 5Y
N/A
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-17.37%
CURRENT VS 3Y AVG
+21.54%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
2.79
median of 388 covered companies
CURRENT VS SECTOR MEDIAN
+214.33%
vs the sector median at left
CeriBell, Inc.
Market Cap
$943.26M
Quick Ratio (Acid-Test)
8.79
TTM Avg
10.63
3Y Avg
7.23
5Y Avg
N/A
Market Cap
$922.50M
Quick Ratio (Acid-Test)
81.42
TTM Avg
11.94
3Y Avg
8.59
5Y Avg
10.34
Market Cap
$915.95M
Quick Ratio (Acid-Test)
1.17
TTM Avg
1.03
3Y Avg
0.92
5Y Avg
1.05
Market Cap
$903.13M
Quick Ratio (Acid-Test)
16.16
TTM Avg
3.88
3Y Avg
3.97
5Y Avg
4.50
Market Cap
$985.79M
Quick Ratio (Acid-Test)
8.42
TTM Avg
11.89
3Y Avg
15.48
5Y Avg
17.00
Market Cap
$989.05M
Quick Ratio (Acid-Test)
16.33
TTM Avg
11.68
3Y Avg
16.13
5Y Avg
16.13
Market Cap
$867.60M
Quick Ratio (Acid-Test)
9.52
TTM Avg
4.26
3Y Avg
6.09
5Y Avg
7.80
Market Cap
$852.55M
Quick Ratio (Acid-Test)
7.96
TTM Avg
6.81
3Y Avg
6.62
5Y Avg
6.62
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CeriBell, Inc. (CBLL) | $943.26M | 8.79 | 10.63 | 7.23 | N/A |
| Arbutus Biopharma Corp (ABUS)vs › | $922.50M | 81.42 | 11.94 | 8.59 | 10.34 |
| Bioventus Inc. (BVS)vs › | $915.95M | 1.17 | 1.03 | 0.92 | 1.05 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | 16.16 | 3.88 | 3.97 | 4.50 |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $985.79M | 8.42 | 11.89 | 15.48 | 17.00 |
| Aktis Oncology, Inc. (AKTS)vs › | $989.05M | 16.33 | 11.68 | 16.13 | 16.13 |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | 9.52 | 4.26 | 6.09 | 7.80 |
| Apnimed, Inc. (APMD)vs › | $866.15M | N/A | N/A | N/A | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $852.55M | 7.96 | 6.81 | 6.62 | 6.62 |
| Alumis Inc. (ALMS)vs › | $844.28M | 6.74 | 5.17 | 5.15 | 5.15 |
Quick Ratio
8.79
Excludes inventory
Current Ratio
9.18
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 8.79 |
| 2026-03-31 | 9.87 |
| 2025-12-31 | 9.35 |
| 2025-09-30 | 12.25 |
| 2025-06-30 | 12.91 |
| 2025-03-31 | 16.81 |
| 2024-12-31 | 16.19 |
| 2024-09-30 | 2.14 |
| 2024-06-30 | 3.53 |
| 2024-03-31 | 0.00 |
| 2023-12-31 | 2.13 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
